Other Current Assets	3 Months Ended
Mar. 31, 2023
Other Current Assets
Other Current Assets	4. Other Current Assets As of March 31, 2023, other current assets included prepaid expenses of $1.7 million, comprised primarily of prepayments of $1.4 million made for the Company’s clinical trials for BP1002 in separate clinical trials for lymphoma and AML, prexigebersen in AML as well as BP1001-A in solid tumors. Additionally, the Company had prepaid expenses related to its insurance policies of $0.2 million and preclinical studies of $0.1 million. As of December 31, 2022, other current assets included prepaid expenses of $1.6 million, comprised primarily of prepayments of $1.3 million made for the Company’s clinical trials for BP1002 in AML and lymphoma, BP1001-A in solid tumors and prexigebersen in AML as well as prepaid insurance of $0.3 million.

Other Current Assets

3 Months Ended

Mar. 31, 2023

4. Other Current Assets

As of March 31, 2023, other current assets included prepaid expenses of $1.7 million, comprised primarily of prepayments of $1.4 million made for the Company’s clinical trials for BP1002 in separate clinical trials for lymphoma and AML, prexigebersen in AML as well as BP1001-A in solid tumors. Additionally, the Company had prepaid expenses related to its insurance policies of $0.2 million and preclinical studies of $0.1 million. As of December 31, 2022, other current assets included prepaid expenses of $1.6 million, comprised primarily of prepayments of $1.3 million made for the Company’s clinical trials for BP1002 in AML and lymphoma, BP1001-A in solid tumors and prexigebersen in AML as well as prepaid insurance of $0.3 million.